Cargando…
A placebo-controlled trial of folic acid and betaine in identical twins with Angelman syndrome
BACKGROUND: Angelman syndrome (AS) is a neurodevelopmental disorder that is caused by maternal genetic deficiency of a gene that encodes E6-AP ubiquitin-protein ligase (gene symbol UBE3A) mapping to chromosome 15q11-q13. AS leads to stiff and jerky gait, excess laughter, seizures, and severe intelle...
Autores principales: | Han, Julia, Bichell, Terry Jo, Golden, Stephanie, Anselm, Irina, Waisbren, Susan, Bacino, Carlos A., Peters, Sarika U., Bird, Lynne M., Kimonis, Virginia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806546/ https://www.ncbi.nlm.nih.gov/pubmed/31640736 http://dx.doi.org/10.1186/s13023-019-1216-0 |
Ejemplares similares
-
Angelman syndrome: review of clinical and molecular aspects
por: Bird, Lynne M
Publicado: (2014) -
Measuring What Matters to Individuals with Angelman Syndrome and Their Families: Development of a Patient-Centered Disease Concept Model
por: Willgoss, Tom, et al.
Publicado: (2020) -
Healthcare burden among individuals with Angelman syndrome: Findings from the Angelman Syndrome Natural History Study
por: Khan, Nasreen, et al.
Publicado: (2019) -
Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS)
por: Tjeertes, Jorrit, et al.
Publicado: (2023) -
Electrophysiological Abnormalities in Angelman Syndrome Correlate With Symptom Severity
por: Hipp, Joerg F., et al.
Publicado: (2021)